secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0000950170-22-023902
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q3 net income plummets to $0.2M on $116.9M revenue; cuts FY2022 guidance
--------------------------------------------------------------------------------

- Net revenue $116.9M (+3% YoY), but net income $0.2M vs $12.6M in Q3 2021.
- Adjusted EBITDA $11.6M, down 46% YoY; adjusted net income $5.1M, down 68%.
- FY2022 revenue guidance lowered to $448-465M, citing challenging physician office environment and reimbursement uncertainty.
- SG&A expenses surged 27% to $79.3M, pressuring margins.
- Cash $108M, debt $72.6M; no share repurchase or dividend changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000095017022023902/0000950170-22-023902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000095017022023902/orgo-20221109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer